JCIC Asset Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.06M Hold
56,139
0.63% 47
2026
Q1
$2.06M Buy
56,139
+21,125
+60% +$1M 0.63% 47
2025
Q4
$1.78M Sell
35,014
-1,085
-3% -$55.5K 0.55% 43
2025
Q3
$2M Buy
+36,099
New +$2.11M 0.63% 42
2025
Q1
$2.54M Sell
36,521
-686
-2% -$56.7K 1.06% 32
2024
Q4
$3.2M Buy
37,207
+665
+2% +$71.9K 1.3% 26
2024
Q3
$4.35M Buy
36,542
+213
+0.6% +$28.4K 1.78% 20
2024
Q2
$5.19M Buy
36,329
+8,777
+32% +$1.16M 2.13% 15
2024
Q1
$3.54M Buy
27,552
+90
+0.3% +$10.7K 1.46% 26
2023
Q4
$2.84M Buy
27,462
+32
+0.1% +$3.17K 1.27% 29
2023
Q3
$2.49M Sell
27,430
-660
-2% -$58.1K 1.26% 28
2023
Q2
$2.27M Buy
28,090
+2,716
+11% +$222K 1.03% 31
2023
Q1
$2.02M Buy
+25,374
New +$1.8M 0.94% 31

Other funds holding NVO

JCIC Asset Management's NVO Position: Q2 2026 in Review

JCIC Asset Management held its Novo Nordisk (NVO) position steady in Q2 2026 at 56,139 shares worth $2.06M. The position accounts for 0.63% of the portfolio, ranked #47.

JCIC Asset Management first reported a position in NVO in Q1 2023 and has held it in 13 quarters since. The position peaked at $5.19M in Q2 2024. 269 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • JCIC Asset Management held 56,139 shares of Novo Nordisk worth $2.06M as of Q2 2026.
  • JCIC Asset Management left its Novo Nordisk share count unchanged in Q2 2026.
  • Novo Nordisk made up 0.63% of JCIC Asset Management's portfolio in Q2 2026, its #47 holding.
  • JCIC Asset Management first reported a position in Novo Nordisk in Q1 2023 and has held it in 13 quarters since.
  • JCIC Asset Management's Novo Nordisk position peaked at $5.19M in Q2 2024.
  • 269 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on JCIC Asset Management's 13F filing for Q2 2026, filed 17 Jul 2026.